Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Corcept Therapeutics (CORT)

Corcept raises 2024 revenue guidance to $640 million to $670 million after 39% Q2 gain

Positive Impact 4 of 5 guidance Written later

Corcept Therapeutics reported second-quarter 2024 revenue of $163.8 million, up 39% from a year earlier, and raised its full-year 2024 revenue guidance to $640 million to $670 million from $620 million to $650 million. Diluted earnings per share were $0.32, compared with $0.25 in the second quarter of 2023, though operating expenses rose to $128.2 million from $88.1 million.

Key points

  • Q2 2024 revenue of $163.8 million, versus $117.7 million in Q2 2023
  • Diluted EPS of $0.32 versus $0.25; net income of $35.5 million versus $27.5 million
  • 2024 revenue guidance raised to $640 million to $670 million from $620 million to $650 million
  • Cash and investments of $492.5 million at June 30, 2024, up from $451.0 million at March 31, 2024

The filing

CompanyCorcept Therapeutics (CORT)
Form8-K, current report
Filed with the SECJul 29, 2024, 4:10 PM ET
Accession number0001628280-24-033281

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.